Adaptive Biotechnologies and Collaborators to Present Eighteen Studies at the American Society of Hematology Annual Meeting 2016

Data demonstrate next-generation sequencing-based minimal residual disease (MRD) detection with the clonoSEQ® Assay is a valuable tool in predicting outcomes in a broad range of blood cancers

SEATTLE--()--Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and its collaborators from pharmaceutical companies and academic centers around the world, will share data further demonstrating the clinical validity and prognostic value of the clonoSEQ Assay for MRD assessment in lymphoid cancers. Data including MRD assessment and T-cell repertoire characterization will be presented in eight oral and ten poster presentations, including five different lymphoid cancer subtypes, at the American Society of Hematology (ASH) Annual Meeting, December 3-6, 2016 in San Diego, CA.

“Providing a diagnostic assay that is ultra-sensitive and standardized to determine treatment response and predict outcomes in people with lymphoid cancers is a priority for Adaptive and furthers our mission to improve patient care,” said Harlan Robins, Chief Scientific Officer and Co-Founder, Adaptive Biotechnologies. “Data presented during ASH demonstrate the breadth of our technology’s capability to predict which patients are at greatest risk of relapse and serve as a reliable surrogate endpoint in pivotal clinical trials.”

Representatives from Adaptive Biotechnologies will be exhibiting at ASH booth #2843 to answer questions about its immunosequencing technology including the clonoSEQ Assay and the immunoSEQ® Assay for research use only.

Oral Presentations:

Abstract #56: CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia
Presenter: Cameron Turtle
Time and Location: Session: 642. Saturday, December 3, 2016: 7:30 AM-9:00 AM. Room 6AB (San Diego Convention Center)

Abstract #246: Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
Presenter: Hervé Avet-Loiseau
Time and Location: Session 653. Saturday, December 3, 2016: 4:00 PM-5:30 PM. Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)

Abstract #238: A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and over the Course of Treatment in Multiple Myeloma Patients
Presenter: Nikhil Munshi
Time and Location: Session 651. Saturday, December 3, 2016: 4:00 PM-5:30 PM. Grand Hall D (Manchester Grand Hyatt San Diego)

Abstract #377: Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma
Presenter: Sandra Susanibar
Time and Location: Session: 651. Sunday, December 4, 2016: 12:00 PM-1:30 PM. Grand Hall D (Manchester Grand Hyatt San Diego)

Abstract #675: Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)
Presenter: Todd Zimmerman
Time and Location: Session 731. Monday, December 5, 2016: 7:00 AM-8:30 AM. Seaport Ballroom DE (Manchester Grand Hyatt San Diego)

Abstract #915: Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens
Presenter: Michael Khodadoust
Time and Location: Session 622. Monday, December 5, 2016: 2:45 PM-4:15 PM. Room 5AB (San Diego Convention Center)

Abstract #1086: Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome
Presenter: Brent Wood
Time and Location: Session: 618. Monday, December 5, 2016: 4:30 PM-6:00 PM. Marriott Grand 11-13 (Marriott Marquis San Diego Marina)

Abstract #1150: Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor
Presenter: Maria-Victoria Mateos
Time and Location: Session 653. Monday, December 5, 2016: 4:30 PM-6:00 PM. Hall AB (San Diego Convention Center)

Poster Presentations:

Abstract #2064: Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma
Presenter: Carolina Schinke
Time and Location: Session: 651. Saturday, December 3, 2016: 5:30 PM-7:30 PM. Hall GH (San Diego Convention Center)

Abstract #1644: Increased Frequencies of PD-1+ CD8+ Marrow-Infiltrating Lymphocytes Associated with Highly Clonal T-Lymphocyte Expansions in Relapsed and Refractory AML Patients but Not Healthy Adults
Presenter: Karolyn Oetjen
Time and Location: Session 616. Saturday, December 3, 2016: 5:30 PM-7:30 PM. Hall GH (San Diego Convention Center)

Abstract #3283: Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients
Presenter: Joaquín Martínez-López
Time and Location: Session 651. Sunday, December 4, 2016: 6:00 PM-8:00 PM. Hall GH (San Diego Convention Center)

Abstract #3313: Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor
Presenter: Asher Chanan-Khan
Time and Location: Session 653. Sunday, December 4, 2016: 6:00 PM-8:00 PM. Hall GH (San Diego Convention Center)

Abstract #3286: Next-Generation Sequencing Based Minimal Residual Disease Assessment in Peripheral Blood RNA from Multiple Myeloma Patients
Presenter: Jeffrey Wolf
Time and Location: Session 651. Sunday, December 4, 2016: 6:00 PM-8:00 PM. Hall GH (San Diego Convention Center)

Abstract #2943: Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma
Presenter: Mark Roschewski
Time and Location: Session 622. Sunday, December 4, 2016: 6:00 PM-8:00 PM. Hall GH (San Diego Convention Center)

Abstract #2673: Towards the Potential Use of In Vitro Expanded Regulatory T-Cells (Tregs) in Aplastic Anemia (AA): Opportunities for Therapy
Presenter: Benedetta Costantini
Time and Location: Session 508. Sunday, December 4, 2016: 6:00 PM-8:00 PM. Hall GH (San Diego Convention Center)

Abstract #4531: Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)
Presenter: Christopher Chiu
Time and Location: Session 653. Monday, December 5, 2016: 6:00 PM-8:00 PM. Hall GH (San Diego Convention Center)

Abstract #3893: Molecular Characterization of Cytotoxic T Cell Repertoire in Aplastic Anemia and Myelodysplastic Syndromes
Presenter: Sofie Lundgren
Session: 508. Bone Marrow Failure: Poster III
Time and Location: Session 508. Monday, December 5, 2016: 6:00 PM-8:00 PM. Hall GH (San Diego Convention Center)

Abstract #4584: Clonal Deletion Plays a Major Role to Achieve Immune Tolerance after Reduced Intensity Unrelated Donor Cord Blood Transplantation (UCBT)
Presenter: Paul Szabolcs
Time and Location: Session 722. Monday, December 5, 2016: 6:00 PM-8:00 PM. Hall GH (San Diego Convention Center)

About Minimal/Measurable Residual Disease

Minimal/measurable residual disease (MRD) refers to cancer cells that remain in the body of a person with lymphoid cancer after treatment. These cells can be present at levels undetectable by traditional morphologic, microscopic examination of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as next-generation sequencing utilized by the Adaptive Biotechnologies clonoSEQ Assay, are needed for reliable detection of MRD at levels below the limits of traditional assessment.

About the clonoSEQ® Assay

The Adaptive Biotechnologies clonoSEQ Assay enables physicians to utilize next-generation sequencing-based MRD detection to inform clinical decision making for patients with lymphoid malignancies. The clonoSEQ assay detects, and quantifies DNA sequences found in malignant cells, which can be tracked throughout treatment. This robust assay provides consistent, accurate measurement of disease burden which allows physicians to visualize response to treatment over time to optimize patient management. Adaptive will be seeking marketing authorization from FDA for the clonoSEQ Assay.

About Adaptive Biotechnologies®

Adaptive Biotechnologies is the pioneer and leader in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information, please visit adaptivebiotech.com.

Contacts

Adaptive Biotechnologies
April Falcone, 206-939-3835
media@adaptivebiotech.com

Contacts

Adaptive Biotechnologies
April Falcone, 206-939-3835
media@adaptivebiotech.com